Progress of chimeric antigen receptor-modified T cell therapy for osteosarcoma
10.3969/j.issn.1001-6325.2018.07.023
- VernacularTitle:嵌合抗原受体基因修饰的T细胞免疫治疗骨肉瘤的研究进展
- Author:
Chen-Xi TONG
1
;
Yin-Hong SONG
Author Information
1. 三峡大学 医学院 病原与免疫学系
- Keywords:
chimeric antigen receptor-modified T(CAR-T)cell;
osteosarcoma;
immunotherapy
- From:
Basic & Clinical Medicine
2018;38(7):1012-1015
- CountryChina
- Language:Chinese
-
Abstract:
Osteosarcoma( OS) is one common type of bone malignancy. Conventional treatments improved survival dramatically. However, conventional therapies have a few effects on patients with metastatic disease. Targeting os-teosarcoma-associated antigen, chimeric antigen receptor-modified T cell( CAR-T) therapy may promote efficacy of treatment. Specific CAR-T treatments of osteosarcoma including targeting HER-2, IL-11Rα, ROR1 and GD2 have shown a certain therapeutic effect on osteosarcoma in some basic and clinical studies.
